[HTML][HTML] International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

…, K Takeshita, A Gopal, S Rule, S De Vos… - Annals of …, 2017 - Elsevier
… In order to evaluate the application of RECIST-like response criteria to lymphoma, a
comparison of the rules for response and progression assessment was conducted. Under the …

Mantle cell lymphoma: evolving management strategies

E Campo, S Rule - Blood, The Journal of the American Society …, 2015 - ashpublications.org
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin’s lymphoma that
generally affects older individuals and continues to have one of the worst outcomes of all …

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis

…, JR Campbell, LP Haraoui, JC Johnston, Z Lan, S Law… - bmj, 2020 - bmj.com
… All 39 studies that reported sensitivity used RT-PCR as the reference standard to rule in …
We also classified the risk as unclear if fewer than two RT-PCRs were used to rule out infection, …

[HTML][HTML] Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

ML Wang, S Rule, P Martin, A Goy… - … England Journal of …, 2013 - Mass Medical Soc
Background Bruton's tyrosine kinase (BTK) is a mediator of the B-cell–receptor signaling
pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK …

Rethinking sex and the Constitution

SA Law - University of Pennsylvania Law Review, 1984 - JSTOR
… At various periods the law has embodied different ideas about sexbased differences. Prior …
marry, and the law declared the married woman dead.'0 The law denied married women both …

Homosexuality and the social meaning of gender

SA Law - Wis. L. Rev., 1988 - HeinOnline
Why do our laws and culture condemn homosexuality? In this Article, Professor Sylvia Law
argues that disapprobation of homosexual behavior is a reaction to the violation of gender …

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

…, S Sun, J Vermeulen, A Rizo, S Rule - The Lancet, 2016 - thelancet.com
Background Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis.
Both ibrutinib and temsirolimus have shown single-agent activity in patients with relapsed …

[HTML][HTML] Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆

M Dreyling, M Ghielmini, S Rule, G Salles… - Annals of …, 2021 - annalsofoncology.org
Diagnosis should be based on a surgical specimen/excisional lymph node (LN) biopsy.
Core biopsies should only be carried out in patients without easily accessible LNs (eg …

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or …

…, H Pylypenko, J Loscertales, A Avigdor, S Rule… - The Lancet …, 2016 - thelancet.com
Background Most patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma
relapse after initial therapy. Bendamustine plus rituximab is often used in the relapsed or …

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

…, M Cheng, D Lee, DM Beaupre, S Rule - Blood, The Journal …, 2015 - ashpublications.org
Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell
lymphoma (MCL) who have received one prior therapy. We report the updated safety and …